$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

$bcrx Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000117184315004473 Filed on August 07, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$10.99M	$25.84M	$1.466M
YoY Change	239.31%	1662.76%	78.56%
Cost Of Revenue	$1.346M
YoY Change
Gross Profit	$9.641M	$25.84M	$1.466M
YoY Change	197.75%	1662.76%	78.78%
Gross Profit Margin	87.75%	100.0%	100.0%
Selling, General & Admin	$2.731M	$3.534M	$2.010M
YoY Change	50.88%	75.82%	40.56%
% of Gross Profit	28.33%	13.68%	137.11%
Research & Development	$20.07M	$16.52M	$11.07M
YoY Change	53.94%	49.31%	-4.02%
% of Gross Profit	208.14%	63.94%	754.91%
Depreciation & Amortization	$50.00K	$40.00K	$50.00K
YoY Change	25.0%	-20.0%	-37.5%
% of Gross Profit	0.52%	0.15%	3.41%
Operating Expenses	$22.80M	$20.06M	$11.07M
YoY Change	74.88%	81.24%	-14.61%
Operating Profit	-$13.16M	$5.342M	-$11.62M
YoY Change	13.37%	-145.98%	-4.29%
Interest Expense	$1.241M	$1.306M	$1.225M
YoY Change	1.97%	6.61%	-4183.33%
% of Operating Profit		24.45%
Other Income/Expense, Net
YoY Change
Pretax Income	-$14.62M	$4.900M	-$14.65M
YoY Change	67.47%	-133.45%	20.38%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$14.62M	$4.901M	-$14.65M
YoY Change	67.46%	-133.46%	20.35%
Net Earnings / Revenue	-133.08%	18.97%	-999.25%
Basic Earnings Per Share	-$0.20	$0.07	-$0.23
Diluted Earnings Per Share	-$0.20	$0.06	-$0.23
COMMON SHARES
Basic Shares Outstanding	73.24M	72.64M	63.65M
Diluted Shares Outstanding	73.26M	76.76M	63.65M

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$70.33M	$94.37M	$132.1M
YoY Change	-44.67%	-28.57%	353.95%
Cash & Equivalents	$46.63M	$76.78M	$121.5M
Short-Term Investments	$23.70M	$17.58M	$10.60M
Other Short-Term Assets	$7.100M	$7.100M	$5.200M
YoY Change	51.06%	36.54%	52.94%
Inventory		$1.308M
Prepaid Expenses
Receivables	$4.300M	$4.300M	$900.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$84.50M	$107.1M	$138.3M
YoY Change	-37.45%	-22.57%	312.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.146M	$1.047M	$200.0K
YoY Change	473.0%	423.5%	-50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$36.10M	$36.10M	$600.0K
YoY Change	11933.33%	5916.67%
Other Assets	$5.239M	$5.699M	$2.900M
YoY Change	249.27%	96.52%	-51.67%
Total Long-Term Assets	$54.45M	$43.09M	$3.700M
YoY Change	2622.7%	1064.68%	-42.19%
TOTAL ASSETS
Total Short-Term Assets	$84.50M	$107.1M	$138.3M
Total Long-Term Assets	$54.45M	$43.09M	$3.700M
Total Assets	$139.0M	$150.2M	$142.0M
YoY Change	1.35%	5.76%	255.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.782M	$3.822M	$2.400M
YoY Change	64.43%	59.25%	140.0%
Accrued Expenses	$23.03M	$19.00M	$11.10M
YoY Change	43.02%	71.18%	18.09%
Deferred Revenue
YoY Change
Short-Term Debt	$30.00M	$30.00M	$30.00M
YoY Change	0.0%	0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$64.44M	$63.77M	$44.90M
YoY Change	29.41%	42.03%	274.17%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$10.30M	$10.30M	$6.900M
YoY Change	171.05%	49.28%	-1.43%
Total Long-Term Liabilities	$10.30M	$10.30M	$6.900M
YoY Change	171.05%	49.28%	-81.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$64.44M	$63.77M	$44.90M
Total Long-Term Liabilities	$10.30M	$10.30M	$6.900M
Total Liabilities	$74.10M	$74.10M	$51.90M
YoY Change	37.99%	42.77%	5.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$492.8M	-$478.2M
YoY Change
Common Stock	$733.0K	$732.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$64.05M	$76.09M	$90.10M
YoY Change
Total Liabilities & Shareholders Equity	$139.0M	$150.2M	$142.0M
YoY Change	1.35%	5.76%	255.89%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$14.62M	$4.901M	-$14.65M
YoY Change	67.46%	-133.46%	20.35%
Depreciation, Depletion And Amortization	$50.00K	$40.00K	$50.00K
YoY Change	25.0%	-20.0%	-37.5%
Cash From Operating Activities	-$12.66M	$18.10M	-$7.100M
YoY Change	47.21%	-354.93%	145.67%
INVESTING ACTIVITIES
Capital Expenditures	-$150.0K	-$360.0K	$0.00
YoY Change	400.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$18.00M	$7.440M	$9.270M
YoY Change	-467.35%	-19.74%	262.11%
Cash From Investing Activities	-$18.14M	$7.070M	$9.260M
YoY Change	-472.48%	-23.65%	266.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$115.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	640.0K	3.250M	105.8M
YoY Change	-81.07%	-96.93%	1884.43%
NET CHANGE
Cash From Operating Activities	-12.66M	18.10M	-7.100M
Cash From Investing Activities	-18.14M	7.070M	9.260M
Cash From Financing Activities	640.0K	3.250M	105.8M
Net Change In Cash	-30.16M	28.42M	107.9M
YoY Change	8517.14%	-73.67%	2071.63%
FREE CASH FLOW
Cash From Operating Activities	-$12.66M	$18.10M	-$7.100M
Capital Expenditures	-$150.0K	-$360.0K	$0.00
Free Cash Flow	-$12.51M	$18.46M	-$7.100M
YoY Change	45.97%	-360.0%	148.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	bcrx	Collaborative And Other Research And Development Revenues CollaborativeAndOtherResearchAndDevelopmentRevenues	2978000
CY2015Q2	bcrx	Available For Sale Securities Accrued Interest AvailableForSaleSecuritiesAccruedInterest	226000
CY2014Q4	bcrx	Available For Sale Securities Accrued Interest AvailableForSaleSecuritiesAccruedInterest	179000
CY2015Q2	bcrx	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	23012000
CY2014Q4	bcrx	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	25459000
CY2015Q2	bcrx	Available For Sale Securities Debt Maturities Maturing After Two Years AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears	13047000
CY2014Q4	bcrx	Available For Sale Securities Debt Maturities Maturing After Two Years AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears	15657000
CY2015Q2	bcrx	Collaborative And Other Research And Development CollaborativeAndOtherResearchAndDevelopment	25710000
CY2014Q2	bcrx	Collaborative And Other Research And Development CollaborativeAndOtherResearchAndDevelopment	1341000
	bcrx	Collaborative And Other Research And Development CollaborativeAndOtherResearchAndDevelopment	30481000
	bcrx	Collaborative And Other Research And Development CollaborativeAndOtherResearchAndDevelopment	2978000
CY2015Q2	bcrx	Collaborative And Other Research And Development Revenues CollaborativeAndOtherResearchAndDevelopmentRevenues	25710000
CY2014Q2	bcrx	Collaborative And Other Research And Development Revenues CollaborativeAndOtherResearchAndDevelopmentRevenues	1341000
	bcrx	Collaborative And Other Research And Development Revenues CollaborativeAndOtherResearchAndDevelopmentRevenues	30481000
CY2015Q2	bcrx	Deferred Collaboration Expense Assets DeferredCollaborationExpenseAssets	288000
CY2014Q4	bcrx	Deferred Collaboration Expense Assets DeferredCollaborationExpenseAssets	177000
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
	bcrx	Deferred Collaboration Expense Changes In Operating Assets And Liabilities DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities	136000
	bcrx	Deferred Collaboration Expense Changes In Operating Assets And Liabilities DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities	-30000
CY2015Q1	bcrx	Maximum Aggregate Offering Price MaximumAggregateOfferingPrice	150000000
CY2013Q4	bcrx	Maximum Aggregate Offering Price MaximumAggregateOfferingPrice	125000000
	bcrx	Number Of Stockbased Compensation Plans NumberOfStockbasedCompensationPlans	2
	bcrx	Receipt Payment Of Foreign Currency Derivative Collateral ReceiptPaymentOfForeignCurrencyDerivativeCollateral
	bcrx	Receipt Payment Of Foreign Currency Derivative Collateral ReceiptPaymentOfForeignCurrencyDerivativeCollateral	-2700000
CY2013Q4	bcrx	Remaining Aggregate Offering Price RemainingAggregateOfferingPrice	10000000
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3822000
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2849000
CY2015Q1	bcrx	Securities Offered SecuritiesOffered	150000000
CY2013Q4	bcrx	Securities Offered SecuritiesOffered	10000000
	bcrx	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Awards Available ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable	1135000
	bcrx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeitures In Period Awards Available SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable	28000
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	73239379
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19001000
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11329000
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-92000
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-130000
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	553610000
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	542943000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5934000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5129000
CY2014Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	110000
CY2015Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	110000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	220000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	220000
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3688000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4038000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3849000
CY2015Q2	us-gaap	Assets Assets	150181000
CY2014Q4	us-gaap	Assets Assets	136874000
CY2015Q2	us-gaap	Assets Current AssetsCurrent	107088000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	89343000
CY2015Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	53643000
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	59348000
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	19000
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	-111000
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	-133000
CY2015Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	53509000
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	59297000
CY2015Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	17584000
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	18232000
CY2015Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	17584000
CY2014Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	41116000
CY2014Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	18232000
CY2015Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	36059000
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76781000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54540000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21164000
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	121519000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	22241000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	100355000
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73168000
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71955000
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73168000
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71955000
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	732000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	720000
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4799000
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14648000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10225000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24787000
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Credit Risk</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"> </div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale receivables discussed above, the majority of the Company’s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</div></div></div></div></div></div></div></div>
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold
CY2014Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	15000
	us-gaap	Cost Of Goods Sold CostOfGoodsSold
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	20500000
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	13085000
	us-gaap	Costs And Expenses CostsAndExpenses	41756000
	us-gaap	Costs And Expenses CostsAndExpenses	23929000
CY2015Q2	us-gaap	Deferred Costs Current DeferredCostsCurrent	101000
CY2014Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	76000
CY2015Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	361000
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	394000
CY2015Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	9959000
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3552000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	94000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	97000
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2015Q2	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	749000
CY2014Q2	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-1824000
	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	1213000
	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-3350000
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3534000
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2013000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7595000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3601000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	8612000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-247000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	5820000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-583000
	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	-332000
	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	-3350000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-1579000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-81000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	625000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-769000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	408000
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-5194000
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-1218000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	1419000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-1000
	us-gaap	Interest Expense InterestExpense	2621000
CY2015Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	116000
CY2014Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	19000
	us-gaap	Interest And Other Income InterestAndOtherIncome	233000
	us-gaap	Interest And Other Income InterestAndOtherIncome	36000
CY2015Q2	us-gaap	Interest Expense InterestExpense	1306000
CY2014Q2	us-gaap	Interest Expense InterestExpense	1225000
	us-gaap	Interest Expense InterestExpense	2467000
CY2015Q2	us-gaap	Interest Payable Current InterestPayableCurrent	4450000
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	6029000
CY2015Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1308000
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	416000
CY2015Q2	us-gaap	Inventory Net InventoryNet	1308000
CY2014Q4	us-gaap	Inventory Net InventoryNet	683000
CY2015Q2	us-gaap	Investments And Cash InvestmentsAndCash	131993000
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	150181000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	136874000
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	63772000
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	57293000
CY2015Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	30000000
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	30000000
	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	0
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4745000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	108173000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3124000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	8243000
CY2015Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	267000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	14372000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16061000
	us-gaap	Net Income Loss NetIncomeLoss	-10263000
	us-gaap	Net Income Loss NetIncomeLoss	-24786000
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	4901000
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-14649000
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	5342000
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11619000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9088000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19005000
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5699000
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6031000
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-102000
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	38000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	19407000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	12651000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	934000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	7000
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5449000
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6172000
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"> </div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Certain balance sheet amounts as of December 31, 2014 have been reclassified to conform to the 2015 presentation.</div></div></div></div></div></div></div></div>
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1175000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	106600000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	24884000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	20900000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3399000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4145000
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	171000
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	128000
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1047000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	207000
CY2015Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	4296000
CY2014Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	3849000
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	12000
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16524000
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11067000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33644000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20250000
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1569000
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	150000
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-478161000
	us-gaap	Revenues Revenues	4924000
CY2015Q2	us-gaap	Royalty Expense RoyaltyExpense	442000
CY2014Q2	us-gaap	Royalty Expense RoyaltyExpense	5000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-467898000
CY2015Q2	us-gaap	Revenues Revenues	25842000
CY2014Q2	us-gaap	Revenues Revenues	1466000
	us-gaap	Royalty Expense RoyaltyExpense	502000
	us-gaap	Royalty Expense RoyaltyExpense	78000
CY2015Q2	us-gaap	Royalty Revenue RoyaltyRevenue	132000
CY2014Q2	us-gaap	Royalty Revenue RoyaltyRevenue	125000
	us-gaap	Royalty Revenue RoyaltyRevenue	1650000
	us-gaap	Royalty Revenue RoyaltyRevenue	1946000
	us-gaap	Revenues Revenues	32668000
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	537000
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	25842000
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	1466000
	us-gaap	Sales Revenue Net SalesRevenueNet	32668000
	us-gaap	Sales Revenue Net SalesRevenueNet	4924000
	us-gaap	Share Based Compensation ShareBasedCompensation	5934000
	us-gaap	Share Based Compensation ShareBasedCompensation	5129000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	1000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	153000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.83
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.87
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.015
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.016
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2362000
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1103000
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.06
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	28000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	9.05
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1135000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9605000
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9779000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.21
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.26
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.98
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y219D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y182D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	933000
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	76089000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	75635000
	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"> </div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div>
CY2015Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	4118000
CY2014Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	76760000
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63647000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72492000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61629000
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72642000
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63647000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72492000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61629000

Files In Submission

Name	View Source	Status
0001171843-15-004473-index-headers.html	Edgar Link	pending
0001171843-15-004473-index.html	Edgar Link	pending
0001171843-15-004473.txt	Edgar Link	pending
0001171843-15-004473-xbrl.zip	Edgar Link	pending
bcrx-20150630.xml	Edgar Link	completed
bcrx-20150630.xsd	Edgar Link	pending
bcrx-20150630_cal.xml	Edgar Link	unprocessable
bcrx-20150630_def.xml	Edgar Link	unprocessable
bcrx-20150630_lab.xml	Edgar Link	unprocessable
bcrx-20150630_pre.xml	Edgar Link	unprocessable
callaghan_innovation.jpg	Edgar Link	pending
exh101_01.jpg	Edgar Link	pending
exh101_02.jpg	Edgar Link	pending
exh101_07.jpg	Edgar Link	pending
exh101_08.jpg	Edgar Link	pending
exh101_09.jpg	Edgar Link	pending
exh101_10.jpg	Edgar Link	pending
exh101_11.jpg	Edgar Link	pending
exh101_12.jpg	Edgar Link	pending
exh101_13.jpg	Edgar Link	pending
exh101_14.jpg	Edgar Link	pending
exh101_15.jpg	Edgar Link	pending
exh101_16.jpg	Edgar Link	pending
exh101_17.jpg	Edgar Link	pending
exh101_18.jpg	Edgar Link	pending
exh101_19.jpg	Edgar Link	pending
exh101_20.jpg	Edgar Link	pending
exh101_21.jpg	Edgar Link	pending
exh101_22.jpg	Edgar Link	pending
exh101_23.jpg	Edgar Link	pending
exh101_24.jpg	Edgar Link	pending
exh101_25.jpg	Edgar Link	pending
exh101_26.jpg	Edgar Link	pending
exh101_27.jpg	Edgar Link	pending
exh101_28.jpg	Edgar Link	pending
exh101_29.jpg	Edgar Link	pending
exh101_30.jpg	Edgar Link	pending
exh101_31.jpg	Edgar Link	pending
exh101_32.jpg	Edgar Link	pending
exh101_33.jpg	Edgar Link	pending
exh101_34.jpg	Edgar Link	pending
exh101_35.jpg	Edgar Link	pending
exh101_36.jpg	Edgar Link	pending
exh102_01.jpg	Edgar Link	pending
exh102_02.jpg	Edgar Link	pending
exh103_01.jpg	Edgar Link	pending
exh103_02.jpg	Edgar Link	pending
exh104_01.jpg	Edgar Link	pending
exh104_02.jpg	Edgar Link	pending
exh105_01.jpg	Edgar Link	pending
exh105_02.jpg	Edgar Link	pending
exh105_03.jpg	Edgar Link	pending
exh106_01.jpg	Edgar Link	pending
exh106_02.jpg	Edgar Link	pending
exh106_03.jpg	Edgar Link	pending
exh106_04.jpg	Edgar Link	pending
exh106_05.jpg	Edgar Link	pending
exh106_06.jpg	Edgar Link	pending
exh106_07.jpg	Edgar Link	pending
exh107_01.jpg	Edgar Link	pending
exh107_02.jpg	Edgar Link	pending
exh107_03.jpg	Edgar Link	pending
exh107_04.jpg	Edgar Link	pending
exh107_05.jpg	Edgar Link	pending
exh107_06.jpg	Edgar Link	pending
exh107_07.jpg	Edgar Link	pending
exh107_08.jpg	Edgar Link	pending
exh107_09.jpg	Edgar Link	pending
exh107_10.jpg	Edgar Link	pending
exh108cr_1.jpg	Edgar Link	pending
exh108cr_2.jpg	Edgar Link	pending
exh108_1.jpg	Edgar Link	pending
exh108_2.jpg	Edgar Link	pending
exh_101.htm	Edgar Link	pending
exh_102.htm	Edgar Link	pending
exh_103.htm	Edgar Link	pending
exh_104.htm	Edgar Link	pending
exh_105.htm	Edgar Link	pending
exh_106.htm	Edgar Link	pending
exh_107.htm	Edgar Link	pending
exh_108.htm	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
exh_322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gfpf10q_080715.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2015 Q3 Form 10-Q Financial Statement

#000117184315004473 Filed on August 07, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2015 Q3 Form 10-Q Financial Statement

#000117184315004473 Filed on August 07, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx